heading · body

Earnings · BOROSCI · Scientific & Laboratory Glassware

Borosil Scientific — the lab-glass arm grows up, slowly and richly priced

Borosil Scientific Ltd

period FY24 → Q4 FY26 added 2026-06-29 score 7/10
earnings-call scientific-glassware BOROSCI india

The Pulse

Borosil Scientific is the lab-glassware leg of the Kheruka family’s Borosil group — the company that makes the beakers, flasks, vials and instruments that pharma quality-control labs, food testers and biotech benches consume. Carved out as its own listed entity only in FY24, it is a clean, near-debt-free, promoter-controlled (68%) business growing revenue steadily to ₹467 crore in FY26 and earning ₹35 crore. The engine inside is the Scientific segment — lab glass, instruments and process systems — which grows mid-teens and earns ~22% segment margins; the drag is a stubbornly loss-making Glassware/pharma-packaging segment. The whole thing earns only modest returns (ROCE 12%, ROE 9.5%), is held back by an inventory pile worth seven months of sales, and pays no dividend while quietly hoarding ₹122 crore in financial investments. Yet the market pays 38× earnings and 3.5× book for it, near a 52-week high. The direction of travel is up and to the right — just gently, and at a price that already assumes the gentleness will turn into something faster.

The Business

Borosil has made scientific and laboratory glassware since 1962, and the brand carries the kind of recognition in Indian labs that takes decades to build. The products are borosilicate-glass consumables — test tubes, pipettes, flasks — sold into regulated end-markets (pharma QC, food and soil testing, microbiology, biotech) where reliability matters more than price. It is, at heart, a razor-and-blades business: labs buy glassware the way kitchens buy crockery, repeatedly and forever.

The group structure matters because the name is shared. “Borosil” is three separately listed companies: Borosil Renewables (solar glass), Borosil Ltd (the consumer kitchenware brand most Indians picture when they hear the name), and Borosil Scientific — this one, the B2B scientific and industrial arm. FY24 was its first year standing alone, hived off through a Composite Scheme of Arrangement with Borosil Limited and Borosil Technologies Limited. The CEO’s framing that year leaned hard on the phrase “this new chapter” — a brand-and-structure reset to let the scientific business be valued on its own terms.

Underneath the headline, the company is really two businesses pulling in opposite directions. The Scientific segment — laboratory glass, equipment and, since the Goel Scientific Glass Works acquisition, chemical process systems (reactors, evaporators, pilot-scale plants) — is the genuine engine. It grew ~17% in FY25 and its segment profit jumped ~50%, lifting its margin past 22%. Alongside it sits a fast-growing in-house instrumentation line, LabQuest, run out of a Pune R&D centre, which has been compounding 30%-plus — the company’s deliberate climb up the value chain from commodity glass toward higher-margin instruments. The second business — Glassware, which bundles pharmaceutical primary packaging (vials, ampoules) with domestic glassware — is the problem child: flat-to-shrinking revenue and a segment loss that widened to roughly ₹14 crore in FY25. Filter paper, a tiny “Others” line, grows fast but is too small to move anything yet.

So what makes it special, to the extent anything does: a trusted six-decade brand, a catalogue broad enough to be a near one-stop scientific supplier, exports to 90-plus countries, and — the sharpest edge management names — audit-gated entry in pharma packaging. Vial and ampoule buyers qualify a supplier through punishing audits; once you are onboarded, switching is expensive, which management calls “a significant entry barrier to competitors.” There is also a regulatory tailwind: new BIS quality standards for lab glassware that took effect in July 2024, which should squeeze non-compliant low-cost players and favour an established name. The catch is that the segment carrying that audit moat is the one losing money — the moat is real but it is not yet earning its keep.

How Management Thinks

The honest constraint here: no earnings-call transcripts were available (screener listed eight quarters of calls but exposed no transcript links logged-out), and the annual-report extracts carried strategy and segment detail but no full chairman’s letter and no dividend discussion. So this read leans on what management has done and the language in the MD&A, more than on what they have said in front of analysts.

What the actions say is consistent and reasonably disciplined. They paid debt down hard — standalone borrowings fell roughly two-thirds in FY25, and interest expense has dwindled to about ₹1 crore. Capex is modest and self-funded, and pointedly directed at the growing Scientific side rather than the loss-making domestic-glassware side — a rational tilt. They grew by acquisition where it made sense, folding in Goel Scientific to open the process-systems niche. The strategy language is expansion-forward across six fronts — instrumentation, pharma packaging, filter paper, water analysis, food-and-nutrition testing, process systems — the posture of a management broadening its range and reaching for higher-value products.

Two things temper the picture. First, the capital-allocation choice that screener’s own algorithm flags: three straight years of profits, three straight years of zero dividend, and no buyback — while ₹122 crore of retained cash sits parked in financial investments earning market returns. For a business that only earns ~12% on its own capital and visibly cannot find enough high-return projects to soak up its cash, hoarding it in a securities portfolio rather than returning it is a defensible-but-debatable call. It isn’t value-destructive — there’s no empire-building, no dilution, no debt-funded payout — but it is cash sitting idle. Second, the upbeat expansion narrative has consistently left the loss-making Glassware segment unaddressed; the reports celebrate the engine and stay quiet on the drag. Credibility-wise, the numbers broadly back the words — revenue and profit have grown each year, the balance sheet genuinely cleaned up — so management does roughly what it says. But you are taking the operating commentary partly on trust here, without the quarter-by-quarter call record to test it against.

Where It’s Going

The trajectory is steady upward with one loud recent data point. Revenue has climbed ₹392 → ₹434 → ₹467 crore over three years, operating margin has inched 12% → 13%, and net profit has risen ₹23 → ₹27 → ₹35 crore. The growth bets are clear: push LabQuest instrumentation, scale up filter paper and pharma-packaging lines, lean on the BIS regulatory tailwind, and keep exporting. None of it is explosive, but it compounds.

The thing to interrogate is the March 2026 quarter, because it carries most of the year. It printed record sales of ₹143 crore, a peak 22% operating margin, and ₹27 crore of net profit — almost the entire FY25 annual profit in a single quarter. Two cautions sit inside that number. The quarter benefited from an unusually low 7% tax rate (versus 30–44% normally), so a chunk of the EPS spike is below-the-line, not operating. And the business is genuinely lumpy: the March quarter is the seasonal peak every year, and the same fiscal year opened with a loss-making June 2025 quarter (sales down to ₹96 crore, a ₹4 crore net loss). Margins have swung between 5% and 22% across twelve quarters. So the honest read on direction is: a real, gradual operating improvement — margins and the Scientific segment are genuinely trending better — wrapped in a great deal of quarterly noise, with FY26’s headline flattered by a tax tailwind.

The genuine tensions: the loss-making Glassware/pharma-packaging segment that needs to either turn or shrink; an inventory-heavy model (roughly 226 inventory days, a ~6–7 month cash-conversion cycle) that structurally caps returns on capital no matter how good the margins look; energy-cost exposure in an energy-intensive manufacturing process; and import competition at the commodity end. Fix the working capital and turn the pharma segment, and the modest 12% ROCE could re-rate higher — that is the bull case the price seems to be reaching for.

The Four Checks

  1. Quality & moat (gate) — 5/10. A decent business with a real but contestable edge. The positives are genuine: a six-decade brand in scientific glassware, a one-stop catalogue, exports to 90-plus countries, audit-gated switching costs in pharma packaging, and a BIS regulatory tailwind that favours compliant incumbents. But the returns tell the truer story — ROE under 10%, ROCE around 12%, a loss-making segment, and exposure to low-cost imports and energy costs. The moat is enough to defend a niche, not enough to command pricing power across the whole business. Decent, not formidable.

  2. Returns on incremental capital & runway — 4/10. This is the weak link. ROCE is ~12% and only recently improving from ~10%; ROE is 9.5%. A rupee reinvested in this business earns modest returns, dragged down by the inventory pile and the loss-making Glassware leg. The runway is real — instrumentation, process systems, pharma packaging, exports all have room — but the tell-tale sign that high-return reinvestment is scarce is that management is parking ₹122 crore in financial investments rather than ploughing it back. The Scientific segment alone earns well; the consolidated engine does not yet.

  3. Capital allocation for the stage — 5/10. Mixed, leaning rational. Good: debt retired, capex self-funded and steered toward the growing segment, sensible bolt-on acquisition (Goel). Questionable: a large idle cash hoard and zero distribution for three years despite consistent profits and a business that can’t fully reinvest its surplus — exactly the situation where returning cash (a buyback, given the no-dividend stance) would be textbook. Not destructive, just not optimal for the stage.

  4. Price — 3/10 (demanding). At 38× earnings and ~3.5× book, near its 52-week high, the market is paying a premium-compounder multiple for a modest-returns (sub-10% ROE) business whose latest headline was partly a tax artefact. The price embeds a re-rating — margin expansion, the pharma turn, a working-capital fix — that the trailing numbers do not yet demonstrate. Reasonable to call it priced for the optimistic case rather than the delivered one.

Engine score: 14/30 (moat 5 + reinvestment 4 + allocation 5). A modest-quality compounder with a clean balance sheet and a good core segment, held back by capital intensity and a loss-making leg — carried at a demanding price.

Sources

  • Annual reports read: FY25 and FY24 (trimmed high-signal sections — MD&A, segment notes, risk register; no full chairman’s letter or dividend note was present in either extract).
  • Financial snapshot: screener.in consolidated, fetched 2026-06-29 — quarterly tables through Mar 2026 (Q4 FY26) and annual P&L FY24–FY26.
  • Concall transcripts: none obtained. Screener listed eight quarters of concalls (Aug 2024 → May 2026) but exposed no transcript links in the logged-out session, and no screener login credentials were available for the fallback. This digest therefore has no quarter-by-quarter management-call commentary; the “How Management Thinks” read leans on annual-report language and on actions visible in the numbers, and is flagged as such. The FY25 segment relabelling (pharma packaging moved into the “Glassware” segment) and the standalone-vs-consolidated profit gap (subsidiaries dragging consolidated earnings below the parent) are the two data quirks worth remembering.
  • Research subfolder (not published): vault/Sources/Earnings/Borosil Scientific Ltd/ — _snapshot.md/.json, _ar_FY25.md + _ar_FY25_sections.md, _ar_FY24.md + _ar_FY24_sections.md, the three _*_digest.md files, and _manifest.json.